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Abstract
Voltage gated calcium channel (VGCC) antibodies are 
generally associated with Lambert-Eaton myasthenic 
syndrome. However the presence of this antibody has 
been associated with paraneoplastic as well as non-
paraneoplastic cerebellar degeneration. Most patients 
with VGCC-antibody-positivity have small cell lung cancer 
(SCLC). Lambert-Eaton myasthenic syndrome (LEMS) 
is an autoimmune disease of the presynaptic part of 
the neuromuscular junction. Its classical clinical triad 
is proximal muscle weakness, areflexia and autonomic 
dysfunction. Fifty to sixty percent of LEMS patients have a 
neoplasia, usually SCLC. The co-occurrence of SCLC and 
LEMS causes more severe and progressive disease and 
shorter survival than non-paraneoplastic LEMS. Treatment 
includes 3,4 diaminopyridine for symptomatic purposes 
and immunotherapy with prednisolone, azathioprine or 
intravenous immunoglobulin in patients unresponsive 
to 3,4 diaminopyridine. Paraneoplastic cerebellar 
degeneration (PCD) is a syndrome characterized with 
severe, subacute pancerebellar dysfunction. Serum is 
positive for VGCC antibody in 41%-44% of patients, 
usually with the co-occurrence of SCLC. Clinical and 
electrophysiological features of LEMS are also present 
in 20%-40% of these patients. Unfortunately, PCD 
symptoms do not improve with immunotherapy. The role 
of VGCC antibody in the immunopathogenesis of LEMS 
is well known whereas its role in PCD is still unclear. 
All patients presenting with LEMS or PCD must be 
investigated for SCLC.
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Core tip: Voltage gated calcium channel (VGCC) 
antibodies are generally associated with Lambert-Eaton 
myasthenic syndrome, but also with paraneoplastic 
or non-paraneoplastic cerebellar degeneration. The 
autoimmune nature of non-tumour Lambert-Eaton 
myasthenic syndrome is reflected in its association with 
various HLA subtypes and other autoimmune diseases 
such as vitiligo, myasthenia gravis and diabetes 
mellitus. The most common tumour associated with 
VGCC-antibody-positivity is small cell lung cancer. 
Knowledge on the relation between cerebellar 
degeneration and VGCC is limited, and treatment 
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response is poor in this group of patients.
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INTRODUCTION
Voltage gated calcium channels are immunologic 
targets for several disease. The calcium channels as a 
target of the pathogenic antibodies in Lambert–Eaton 
myasthenic syndrome (LEMS) was first suggested by 
Fukunaga et al[1] in 1983. Subsequent studies showed 
antibodies against P/Q type calcium channel as the 
most prominent in these patients[2].
Although voltage gated calcium channel (VGCC) 
antibodies are generally associated with LEMS, usually 
seen as a paraneoplastic syndrome with small cell lung 
cancer (SCLC), rarely non-paraneoplastic cerebellar 
degeneration may also occur in the presence of this 
antibody[3,4]. VGCC antibody positivity is observed 
in 85%-90% of LEMS patients whereas the ratio 
approaches 100% in LEMS patients with SCLC[5]. 
Approximately 40% of patients with subacute onset 
cerebellar degeneration, usually with SCLC, have VGCC 
antibody positivity[3,6]. Moreover these antibodies can 
also be detected in SCLC patients without neurological 
involvement[5].
VGCC 
The VGCC is crucial in the depolarization of the cell 
membrane and cellular influx of calcium in response to 
action potential. It functions as a secondary messenger 
in electrical signalization and initiates several cellular 
mechanisms[7]. They are found in several cells, such 
as smooth and skeletal muscle fibers, endocrine 
cells, neurons[7]. The channel also locates on the 
presynaptic membrane of the axon terminal. VGCC 
opens by action potential and leads to the entry of 
calcium ions into the axon terminals. Calcium influx 
results in movement of acetylcholine vesicles towards 
the presynaptic membrane and acetylcholine is 
released into the synaptic cleft. In striated muscles, 
the VGCC on the membrane of transverse tubules 
directly activates ryanodine-sensitive calcium channels 
in the sarcoplasmic reticulum and initiates rapid 
contraction[7,8].
VGCC is divided into five types: L, P/Q, N, R, T 
depending on tissues and pharmacological properties[7]. 
The channel contains 4 or 5 subunits (α1, α2/δ, b 
and g).The ion transition pore responsible for the 
biochemical and electrophysiological properties is 
the α1 subunit. This subunit contains six helical 
transmembrane segments (S1-S6) and 4 domains 
(Ⅰ-Ⅳ)[9] (Figure 1). Ten different α1 subunits have 
been defined and CaV2.1 α1 subunit is found in P/Q 
type VGCC[7]. Voltage sensors are located in the S4 
segment. The S5 and S6 segments are sensitive to 
calcium[9]. Antibodies against the S5-6 segments of 
α1 subunit are detected in 50% of LEMS patients[5]. 
Other antibodies detected in LEMS patients are against 
domain Ⅳ and β subunit[5,10]. However, the pathogenic 
role of b subunit antibodies is still controversial due to 
its intracellular location.
Antibodies to P/Q type channels are responsible for 
clinical symptoms of LEMS[5]. Thirty to forty percent of 
the patients with antibodies to P/Q type channels also 
have antibodies to N-type channels whereas in 25% 
patients also have antibodies to L-type channels[5]. 
Antibodies to N and P/Q type channels are detected 
in 40% of patients with cerebellar ataxia associated 
with SCLC[9]. Sry-like high-mobility group box (SOX-1), 
zic-4, anti-Hu are other antibodies detected in the sera 
of patients with PCD and SCLC and approximately70% 
of the patients have one of these antibodies[6].
LEMS
LEMS is the autoimmune disease of the presynaptic 
nerve terminals. It is a rare disease with a prevalence 
of 2.3 per million and an incidence of 0.5 per million[11]. 
It is associated with SCLC in 50%-60% of patients. As 
the clinical and laboratory features differ in patients 
with and without SCLC, the disease is divided into two 
groups as LEMS with SCLC (SCLC-LEMS) and non-
tumour (NT-LEMS).The age of onset is 50 years or 
above and there is a male predominance in patients 
with SCLC-LEMS. On the other hand NT-LEMS can be 
seen in all age groups with a peak at the age of 35 and 
60 and a female predominance[12].
LEMS hardly occurs in childhood; only 5% of LEMS 
patients are less than 18-year-old[13]. Our youngest 
LEMS patient was a eight year-old female.
Pathogenesis
LEMS is a disorder due to antibodies against P/Q type 
VGCC. VGCC antibodies interact with extracellular 
S5 and S6 segments of domain Ⅱ, Ⅲ and Ⅳ of α1 
subunit and reduce the number of ion channels by 
cross binding[5,14-16]. The antibodies can also bind to 
other VGCC types without causing any dysfunction. 
Although VGCC antibodies usually generate an 
immune reaction, the response to epitopes varies in 
LEMS patients[17]. Antigenic modulation followed by 
clustering and reduction of VGCC leads to reduction 
in quantal release of acetylcholine in synapses and 
results in muscle weakness[18]. The down-regulation 
of the receptors of parasympathetic and sympathetic 
neurons that cause autonomic dysfunction is also 
associated with these antibodies.
VGCC antibodies can be detected by radioimmunoassay 
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in 85%-90% of LEMS patients and 100% of patients 
with SCLC-LEMS[17,19,20]. P/Q type VGCC are expressed 
on SCLC cells and this expression results in production 
of antibodies and cross-reaction with presynaptic 
VGCC[21]. As the immune reaction is initiated early in 
tumour development, the diagnosis of LEMS frequently 
precedes the diagnosis of the SCLC[16]. Besides, VGCC 
antibodies may be detected in 3%-5% of patients 
with SCLC without muscle weakness or autonomic 
dysfunction[16]. 
Approximately 10%-15% of LEMS patients do 
not have serum antibodies. However, their serum 
reproduces LEMS-like symptoms when it transferred to 
mice. This finding suggests the presence of antibodies 
at very low concentrations or antibodies against 
different epitopes of the VGCC that are undetected 
by routine tests[5]. Antibodies against synaptotagmin, 
a synaptic vesicle protein, have been found in some 
seronegative and seropositive LEMS patients[14,22]. 
Although there is no evidence on their pathogenic role, 
the blocking of synaptotagmin, which is a Ca2+ sensor 
in the membrane of the pre-synaptic axon terminal 
may explain the muscle weakness in LEMS[23]. Another 
such antibody, whose pathogenic role is unclear, is 
against “sry-like high-mobility group box” (SOX-1) 
proteins. This antibody is positive in 67% of SCLC-
LEMS patients, 22%-32% of patients with SCLC 
without LEMS and only in 5% of NT-LEMS patients[19].
The role of T lymphocytes in LEMS pathogenesis is 
unclear. Thymus and other lymphoid organs involved in 
myasthenia gravis (MG) do not present abnormalities 
in LEMS and the presynaptic terminals do not reveal 
T lymphocyte collection[16]. However regulatory T 
lymphocytes are down-regulated in SCLC-LEMS 
patients, but not in SCLC patients without LEMS, which 
suggests the dysfunction of regulatory T lymphocyte in 
SCLC-LEMS pathogenesis[24].
Unlike SCLC-LEMS patients, the trigger of the 
immune response is not defined in NT-LEMS.Various 
HLA associations, also reported with other autoimmune 
diseases, have been documented: Approximately two-
third of patients have HLA-B8 (HLA class Ⅰ) and HLA-
DR3, -DQ2 (HLA class Ⅱ) alleles[25,26]. Supporting this 
phenomenon, monozygous twins have been reported 
where one has LEMS and VGCC antibodies, and the 
other, myasthenia gravis and acetylcholine receptor 
antibodies[27]. On the other hand, HLA association was 
not found in SCLC-LEMS patients: because tumoral 
cells do not have strong HLA class Ⅰ antigen expression, 
these molecules are possibly not involved in the 
immunopathogenesis[25]. These observations resemble 
the difference between MG with and without thymoma 
and reveal the existence of different autoimmune 
mechanisms in paraneoplastic disorders[16].
Clinical features
The classical triad of LEMS is proximal weakness, 
reduced tendon reflexes and autonomic dysfunction[16].
Proximal weakness, more prominent in lower 
extremities, is the first symptom in 80% of patients[16,28]. 
In the course of the disease, 80% of patients suffer 
from proximal weakness in both upper and lower 
extremities[28,29]. Facial, bulbar and distal weakness are 
also frequent[16]. The weakness is more severe and 
rapidly progressive in SCLC-LEMS patients[16,28].
Autonomic dysfunction, observed in 80%-96% of 
patients, is the most common symptom although it 
is less disturbing than muscle weakness[12,28]. Erectile 
dysfunction and constipation are more frequent 
symptoms than urinary retention, dry eye and reduced 
sweating[5]. The rate and the nature of autonomic 
symptoms do not differ between SCLC-LEMS and NT-
LEMS[16].
On neurological examination deep tendon reflexes 
are generally reduced or absent. However maximal 
isometric contraction of the muscle for 10 to 15 s 
may lead to the appearance of previously depressed 
or absent deep tendon reflexes and temporarily 
improve muscle strength, which is called “Post-exercise 
facilitation”. This phenomenon, a characteristic feature 
of LEMS, is not sensitive[5]. This phenomenon may 
also mask the reduction of deep tendon reflexes in 
40% of patients so the neurological examination 
must be repeated after a resting period to verify the 
diagnosis[5].
Associated diseases
The most common co-existence of LEMS is with 
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Figure 1  The structure of Voltage gated calcium channels.
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SCLC, reported in 50%-60% of LEMS patients[12]. 
Besides, 0.5%-3% of SCLC patients have LEMS[25]. 
This co-existence results in a more severe and rapidly 
progressive neurological disease with shortened 
survival compared to NT-LEMS which has a near 
normal survival[16]. Moreover SCLC-LEMS patients tend 
to be younger than other SCLC patients[19].
Older age, tobacco use, increased ESR support 
the probability of underlying SCLC. In a Dutch-English 
cohort study a scoring system called DELTA-P was 
implemented to predict SCLC in LEMS[12]. According 
to DELTA-P, dysarthria, dysphagia, chewing or neck 
weakness(D), erectile dysfunction (E), loss of weight 
(L), tobacco use (T), age of onset more than 50 (A) 
and Karnofsky performance less than 60 (P) have a 
predictive value: patients with a DELTA-P score three 
or more have higher than 94% risk of having SCLC.
The distinction of SCLC-LEMS from NT-LEMS is 
important, as treatment options and outcome are 
different. For this reason, new markers to diagnose 
SCLC-LEMS are still under investigation. Although 
SOX-1antibodies are detected in half of the SCLC-
LEMS patients, the absence of a commercial kit, and 
the presence of these antibodies in NT-LEMS limit their 
use for differential diagnosis[30]. Another study revealed 
that VGCC antibody against domain IV positivity is 
more common in NT-LEMS patients than in SCLC-
LEMS patients, but this is not used for clinical purposes 
yet[17].
The co-existence of LEMS with other malignancies 
such as non-small cell lung cancer, prostate carcinoma, 
orthymoma has been reported rarely[13] and a random 
association could not be excluded[5]. 
In children, the disease is generally non-paraneoplastic; 
lymphoproliferative malignancy and neuroblastoma are 
rare associations[13,31]. In accordance with the literature, 
our pediatric patient did not have any neoplasm.
Other autoimmune diseases such as thyroid 
disorders, alopecia, diabetes mellitus, MG can occur 
in NT-LEMS patients probably due to the presence of 
various HLA subtypes contributing to autoimmunity[32]. 
In our clinical experience, NT-LEMS patients may have 
associated vitiligo and myasthenia.
Diagnosis
The time lag between the onset of the symptoms and 
diagnosis is approximately 4 mo in SCLC-LEMS and 12 
mo in NT-LEMS[12,29].
In patients with suspected LEMS, electrophysiological 
studies with repetitive nerve stimulation are among the 
most important diagnostic tests. The compound muscle 
action potential (CMAP) is low after the first stimulation 
and decreases further after repetitive stimulation at 
2-5 Hz[33]. At least 10% reduction in CMAP after low 
frequency stimulation is considered abnormal and 
observed in 94%-98% of patients[34,35]. However, 
this finding may also be present in MG patients. To 
distinguish these two diseases, nerve stimulation at 
high frequency (50 Hz) or, as a less painful method for 
the patient, post-exercise measurement is employed, 
which increases CMAP by more than 100% in LEMS 
patients[34,35]. Optimum results will be obtained if 
treatment is interrupted 12 h before the study and the 
muscle temperature is above32 ℃.
Although single fiber EMG is a sensitive test, it 
is used in combination with other tests as it cannot 
distinguish between MG and LEMS[33]. LEMS patients 
have increased jitter like MG patients. In case of 
severe neuromuscular junction dysfunction, the 
conduction defect in muscle fiber causes a decrease 
in amplitude and duration of motor unit potential as in 
myopathies[36].
VGCC antibodies are detected by RIA in 85%-90% of 
LEMS and in almost 100% of SCLC-LEMS patients[17,19,20]. 
Although the presence of VGCC antibodies supports 
the diagnosis of LEMS, the absence of antibodies in a 
patient with typical clinical features does not exclude the 
diagnosis.
In 50% of patients SCLC-LEMS, LEMS symptoms 
precede the diagnosis of SCLC. In addition to scoring 
systems such as DELTA-P, all patients with the diagnosis 
of LEMS must undergo computerized tomography of the 
thorax and positron emission tomography (PET). If the 
results are negative, the screening must be repeated 
every 3-6 mo until the second year of the disease[37].
The differential diagnosis of LEMS from seronegative 
and atypical myasthenia gravis can be challenging. 
Some clinical findings may be helpful: the progression 
of weakness is in the craniocaudal direction in MG and 
the reverse in LEMS; ptosis and facial weakness are 
less common and severe in LEMS. Electrophysiological 
studies described above and serological findings assist 
the clinician in the differential diagnosis. 
LEMS with a subacute course can be misdiagnosed 
as Guillain Barré syndrome (GBS); the presence of 
sensorial symptoms, neuropathic pain, and elevated 
CSF protein favor the diagnosis of GBS. Amyotrophic 
lateral sclerosis may constitute another differential 
diagnosis, and can be distinguished by the asymmetrical 
weakness starting in the upper extremities and the 
presence of upper motor neuron signs.
Treatment
The first choice for symptomatic treatment is 3,4 
diaminopyridine[38]. This molecule blocks presynaptic 
voltage-gated potassium channels and provides a 
prolonged action potential which increases the quantal 
release of synaptic acetylcholine[39]. All randomized 
controlled studies of 3,4 diaminopyridine showed 
improvement in muscle strength and CMAP amplitudes. 
The drug is well tolerated although adverse effects like 
perioral and digital paresthesias and gastrointestinal 
symptoms are not uncommon. Seizures, which is the 
most frequent severe side effect, have been reported at 
high doses exceeding 100 mg/d[40,41]. In our experience, 
the drug is well tolerated and improves muscle 
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strength at the dose of 40-60 mg/d.
Other treatments, which can increase the concentration 
of acetylcholine in synaptic cleft, are pyridostigmine 
and acetylcholine esterase inhibitors but they are not as 
effective as they are in MG patients[42].
In case of limited response to 3,4 diaminopyridine, 
immunosuppressive treatments must be considered. 
The combination of prednisolone and azathioprine is 
well studied and documented in LEMS patients[38,42]. 
Although there is not sufficient data, mycophenolate 
mofetil, cyclosporine and rituximab are also drugs 
employed in LEMS treatment[16,43]. Intravenous 
immunoglobulin (IVIg), another treatment option in 
paraneoplastic syndromes and MG, can also be used 
in LEMS. European Federation of Neurological Societies 
(EFNS) guidelines recommend IVIg in both SCLC-
LEMS and NT-LEMS[44]. IVIg is also recommended in 
pregnant patients, as transplacental transmission of 
IgG antibodies may cause neonatal LEMS[45]. IVIg is 
generally preferred as its side effects are rare and it 
is easily used for the maintenance treatment, which 
is usually needed in LEMS patients. Plasma exchange 
whose effect is comparable to IVIg may carry technical 
difficulties and slightly higher rate of complications[46].
In patients with SCLC, the treatment of the tumour 
is crucial. The survival of SCLC-LEMS patients is 
better than in patients with SCLC alone, but there is 
no relation with VGCC or SOX-1 antibody positivity 
and survival[17,19]. The better prognosis in these 
patients may be correlated with the diagnosis time 
that is earlier in LEMS patients[12,29]. Moreover HLA-B8 
positivity is related to prolonged survival in SCLC-LEMS 
patients[47].
Maintenance of optimal body weight, rehabilitation, 
frequent examinations for complications such as 
respiratory infections, and avoidance of drugs impairing 
neuromuscular transmission are other important 
aspects of the treatment.
CEREBELLAR DEGENERATION 
ASSOCIATED WITH VGCC ANTIBODY
Paraneoplastic cerebellar degeneration (PCD) is 
a syndrome characterized by subacute cerebellar 
dysfunction[48]. Clinical and pathological features of the 
syndrome were described by Brain and Wilkinson[49] in 
1965 by the evaluation of 13 patients and 6 autopsy 
cases. Diffuse loss of Purkinje cells is the pathologic 
hallmark of the disease and usually accompanied by 
thinning of granular and molecular layers, degeneration 
of long tracts of spinal cord, dentate and olivary nuclei[4].
Most common neoplasms associated with cerebellar 
degeneration are lung, breast, ovarian cancers and 
Hodgkin lymphoma[48]. Onconeural antibodies such 
as anti-Hu, anti Yo, anti-Ri, anti-CV2, anti-Tr, anti-
Ma, anti-Ta, anti zic 4, and anti-mGluR1 as well as 
VGCC antibody can be detected in PCD[50]. Clinical 
presentation, neuropathological findings and treatment 
responses of patients vary according to the type of 
the onconeural antibody, suggesting distinct immune 
mechanisms related to different antibodies[4].
Pathogenesis
Antibodies against VGCC of the P/Q type or N type are 
found in 41%-44% of PCD patients, generally associated 
with SCLC[3,6,9]. The P/Q type VGCC is highly expressed 
in cerebellar Purkinje cells and in the molecular layer of 
the cerebellum[9,51]. About 20%-40% of these patients 
also have clinical or electrophysiological diagnosis of 
LEMS[3,6]. Neuropathological findings of PCD with LEMS 
(PCD-LEMS) were reported in 1973 by Satoyoshi et 
al[51] for the first time. In a postmortem study of three 
PCD-LEMS patients with VGCC antibodies, 70%-80% 
of reduction in P/Q type VGCC of the molecular layer; 
loss of Purkinje cells and gliosis in the cerebellar cortex 
were observed[9,51]. The role of VGCC antibodies in 
the pathogenesis of PCD is still unclear. In a recent 
experimental study, antibodies of the IgG type purified 
from the serum of two VGCC antibody-positive patients 
with SCLC, one with PCD-LEMS and another patient 
with isolated LEMS were given to mice intrathecally, 
the antibodies associated with PCD-LEMS but not from 
isolated LEMS patients caused cerebellar ataxia in 
mice[52]. This finding suggests the presence of different 
epitopes of P/Q type VGCC antibodies which inhibit 
VGCC’s function in cerebellum, or of other additional, 
yet undiscovered pathogenic antibodies[52].
Clinical, laboratory and radiological features
Subacute and rapidly progressive gait unsteadiness is 
the presenting symptom of cerebellar degeneration[50]. 
Gait and limb ataxia, diplopia, dysarthria are the other 
prominent symptoms[50]. Sometimes these complaints 
may preceded by dizziness, nausea and viral infection-
like symptoms[50]. Occasionally other signs and 
symptoms such as dysphagia, nystagmus and sensory 
deficits can be also seen during the course. Patients 
who had concomitant LEMS may also show proximal 
weakness and autonomic symptoms in addition to 
cerebellar symptoms[4].
The cerebrospinal fluid (CSF) may show mild 
lymphocytic pleocytosis with elevated protein and 
oligoclonal bands[48]. VGCC antibodies may also 
be detected in CSF and there is some evidence of 
intrathecalsynthesis of the antibodies, and detected in 
about 25% of the patients[3]. This low percentage may 
be explained by the absence of CSF analysis in some 
cases and further studies are needed to increase the 
rate of antibody presence in CSF.
Initial brain magnetic resonance images or tomography 
are normal in most patients[4] although in early stages 
of the disease fluorodeoxyglucose-PET scans may show 
cerebellar hypermetabolism[50,53], whereas cerebellar 
atrophy and cerebellar hypometabolism are seen in the 
advanced stage of the disease[50]. 
Treatment
Treatment of the underlying malignancy has the 
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priority like other paraneoplastic syndromes[50]. 
Corticosteroids, plasma exchange, IVIG, tacrolimus and 
cyclophosphamide are the immunotherapeutic options 
to be used concurrently with tumour therapy, but 
most of the cases did not show sufficient improvement 
despite treatment[50]. Unlike in LEMS, immunotherapy 
does not result in symptomatic improvement in PCD: 
this suggests PCD may be associated with irreversible 
damage of Purkinje cells[3].
NON-PARANEOPLASTIC CEREBELLAR 
DEGENERATION WITH VGCC ANTIBODY
VGCC antibodies were also found in a few patients 
with non-paraneoplastic cerebellar degeneration. 
In a study of the antibody profile of 67 cases with 
sporadic, late-onset cerebellar ataxia of unknown 
etiology, VGCC antibodies were found in 12%[54]. 
Two cases with NT-LEMS who developed cerebellar 
ataxia during the course of their disease had VGCC 
antibodies in serum and CSF. Cerebellar symptoms of 
these patients showed no improvement with different 
immunotherapies, as in PCD[55]. However a few 
cases of non-paraneoplastic cerebellar degeneration 
showed favorable outcome under rituximab and IVIg 
treatment[56,57].
CONCLUSION
Diseases related to VGCC antibodies are usually 
associated with SCLC. Therefore, SCLC should be 
investigated in patients with LEMS and/or cerebellar 
degeneration. The role of VGCC antibodies in the 
immunopathogenesis of LEMS is clear, however 
their role in cerebellar degeneration is not known. 
Determination of the effect of VGCC antibodies on 
the pathogenesis of cerebellar degeneration may 
contribute to the design of more efficient treatment 
strategies. Therefore, experimental models and 
pathologic studies that investigate the effect of 
immune mechanisms at molecular level in the tissue 
are needed.
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